Adjuvant systemic therapies are now routinely used following resection of stage III
melanoma, however accurate prognostic information is needed to better stratify patients. We …

Melanoma is currently divided on a genetic level according to mutational status. However,
this classification does not optimally predict prognosis. In prior studies, we have defined …

Purpose: Previously identified transcriptomic signatures have been based on primary and
metastatic melanomas with relatively few American Joint Committee on Cancer (AJCC) …

Background Current clinical and histopathological criteria used to define the prognosis of
melanoma patients are inadequate for accurate prediction of clinical outcome. We …

Purpose As a result of the questionable risk-to-benefit ratio of adjuvant therapies, stage II
melanoma is currently managed by observation because available clinicopathologic …

Purpose: Patients with macroscopic stage III melanoma represent a heterogeneous cohort
with average 5-year overall survival rates of< 30%. With current algorithms, it is not possible …

Melanoma is the most aggressive type of skin cancer in the United States with an increasing
incidence. Melanoma lesions often exhibit high immunogenicity, with infiltrating immune …

Background The process of malignant transformation, progression and metastasis of
melanoma is poorly understood. Gene expression profiling of human cancer has allowed for …

Purpose: Biomarkers are needed to stratify patients with stage II–III melanoma for clinical
trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk …

In melanoma, there is an urgent need to identify novel biomarkers with prognostic
performance superior to traditional clinical and histological parameters. Gene expression …